Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Irene Braña Garcia"'
Autor:
Seock-Ah Im, Antoine Italiano, Jean-Yves Blay, Arun Azad, Victor Moreno, Christine L. Hann, Peter J. O'Dwyer, Matthew L. Hemming, Anastasia Wyce, Michael T. McCabe, Geoffrey I. Shapiro, Antara Datta, Thierry Horner, Philippe A. Cassier, Sarina Anne Piha-Paul, Sophie Cousin, Christophe Le Tourneau, Brandon E. Kremer, Ruth Plummer, Christopher A. French, Ahmed Khaled, Vicki L. Keedy, Jose Manuel Trigo, Johann S. de Bono, Yuehui Wu, Arindam Dhar, Geraldine Ferron-Brady, Marie-Paule Sablin, Shawn W. Foley, Irene Braña Garcia
Publikováno v:
International Journal of Cancer. 150:993-1006
Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study in solid tumors resulted in the selection of a 75 mg once daily dose of the besylate formulation of molibresib as the reco
Autor:
Urs Müller-Richter, Coro Bescós Atín, Selvam Thavaraj, Paolo Bossi, Alba de Pablo García-Cuenca, Jorge Pamias Romero, Luigi Lorini, Margarita Alberola Ferranti, Sara Simonetti, Paolo Nuciforo, Manel Sáez Barba, Irene Braña Garcia
Publikováno v:
Cancers
Scientia
Cancers, Vol 13, Iss 3696, p 3696 (2021)
Scientia
Cancers, Vol 13, Iss 3696, p 3696 (2021)
Simple Summary Oral potentially malignant disorders (OPMDs) include a group of oral mucosal diseases with different morphological characteristics that are able to progress to oral squamous cell carcinoma (OSCC). Given OSCC’s poor prognosis and high
Autor:
Sophie, Cousin, Jean-Yves, Blay, Irene Braña, Garcia, Johann S, de Bono, Christophe, Le Tourneau, Victor, Moreno, Jose, Trigo, Christine L, Hann, Arun A, Azad, Seock-Ah, Im, Philippe A, Cassier, Christopher A, French, Antoine, Italiano, Vicki L, Keedy, Ruth, Plummer, Marie-Paule, Sablin, Matthew L, Hemming, Geraldine, Ferron-Brady, Anastasia, Wyce, Ahmed, Khaled, Antara, Datta, Shawn W, Foley, Michael T, McCabe, Yuehui, Wu, Thierry, Horner, Brandon E, Kremer, Arindam, Dhar, Peter J, O'Dwyer, Geoffrey I, Shapiro, Sarina A, Piha-Paul
Publikováno v:
International journal of cancerREFERENCES. 150(6)
Molibresib is an orally bioavailable, selective, small molecule BET protein inhibitor. Results from a first time in human study in solid tumors resulted in the selection of a 75 mg once daily dose of the besylate formulation of molibresib as the reco
Autor:
Jean-Yves Blay, Thierry Horner, Seock-Ah Im, Peter J. O'Dwyer, Christine L. Hann, Christophe Le Tourneau, Sarina Anne Piha-Paul, Victor Moreno, Geraldine Ferron-Brady, Arindam Dhar, Brandon E. Kremer, Irene Braña Garcia, Johann S. de Bono, Arun Azad, Geoffrey I. Shapiro, Sophie Cousin, Jose Manuel Trigo, Antara Datta, Yuehui Wu
Publikováno v:
Journal of Clinical Oncology. 38:3618-3618
3618 Background: Molibresib is an orally available, small molecule bromodomain and extra-terminal domain (BET) protein inhibitor under investigation for treatment of advanced solid tumors. Methods: This was an open-label, single- and repeat-dose, 2-p
Autor:
Luigi Lorini, Coro Bescós Atín, Selvam Thavaraj, Urs Müller-Richter, Margarita Alberola Ferranti, Jorge Pamias Romero, Manel Sáez Barba, Alba de Pablo García-Cuenca, Irene Braña García, Paolo Bossi, Paolo Nuciforo, Sara Simonetti
Publikováno v:
Cancers, Vol 13, Iss 15, p 3696 (2021)
Oral squamous cell carcinoma (OSCC) is a very aggressive cancer, representing one of the most common malignancies worldwide. Oral potentially malignant disorders (OPMDs) regroup a variegate set of different histological lesions, characterized by the
Externí odkaz:
https://doaj.org/article/cfe3aed9a99346eb866c3ee45fe28470